Multicenter analysis of MRI-guided, stereotactic body radiotherapy as ablative treatment for lymph nodal metastases of the abdomen and pelvis
MRI-guided SBRT for abdominal and pelvic LNM achieved durable local tumor control rates of over 85% after two years and was associated with a favorable toxicity profile. MR-guided SBRT is a valid option for ablative treatment of nodal oligometastases, even for the difficult to treat intra-abdominal targets.
Authors
- Stefanie Corradini (ORCID: https://orcid.org/0000-0001-8709-7252)
- Sebastian Marschner (ORCID: https://orcid.org/0000-0002-8121-358X)
- Annika Lattermann
- Sebastian Regnery (ORCID: https://orcid.org/0000-0002-6820-884X)
- Matthias Gückenberger (ORCID: https://orcid.org/0000-0002-7146-9071)
- Nicolaus Andratschke (ORCID: https://orcid.org/0000-0003-3647-5916)
- Panagiotis Balermpas (ORCID: https://orcid.org/0000-0001-5261-6446)
- Juliane Hörner‐Rieber (ORCID: https://orcid.org/0000-0003-3911-4438)
- Karoline Leger
- Jens von der Grün (ORCID: https://orcid.org/0000-0002-9371-7814)
- Esther G.C. Troost (ORCID: https://orcid.org/0000-0001-9550-9050)
- Philipp Hoegen-Saßmannshausen
- Dinah Konnerth
- Stephanie Tanadini-Lang
Institutions
- Heidelberg University (DE)
- University Hospital Heidelberg (DE)
- LMU Klinikum (DE)
- Düsseldorf University Hospital (DE)
- University Hospital of Zurich (CH)
- University Hospital Carl Gustav Carus (DE)
- Heinrich Heine University Düsseldorf (DE)
- Ludwig-Maximilians-Universität München (DE)
Publication Details
- Journal
- Radiotherapy and Oncology
- Published
- 2025-10-28
- DOI
- https://doi.org/10.1016/j.radonc.2025.111237
- Primary Topic
- Hepatocellular Carcinoma Treatment and Prognosis
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Pfizer
- AstraZeneca
- Sanofi
- Varian Medical Systems
- ViewRay